Table 2 Demographics and disease characteristics of patients in the training cohort
Variables | PTR | Non-PTR | p value |
|---|---|---|---|
(n = 4561) | (n = 1808) | ||
Age n (%) | |||
< 60 | 1881 (41.24%) | 819 (45.30%) | 0.003 |
≥ 60 | 2680 (58.76%) | 989 (54.70%) | |
Gender n (%) | |||
Male | 2496 (54.72%) | 1099 (60.79%) | < 0.001 |
Female | 2065 (45.28%) | 709 (39.21%) | |
Race n (%) | |||
Black | 3424 (75.07%) | 1347 (74.50%) | 0.859 |
White | 714 (15.65%) | 286 (15.82%) | |
Other | 423 (9.27%) | 175 (9.68%) | |
Grade n (%) | |||
I and II | 3226 (70.73%) | 1387 (76.71%) | < 0.001 |
III and IV | 1335 (29.27%) | 421 (23.29%) | |
Primary site n (%) | |||
Proximal colon | 2210 (8.45%) | 443 (24.50%) | < 0.001 |
Distal colon | 1335 (29.27%) | 355 (19.63%) | |
Rectum | 921 (20.19%) | 982 (54.31%) | |
Other | 95 (2.08%) | 28 (1.55%) | |
Histology type n (%) | |||
AC | 4071 (89.26%) | 1713 (94.75%) | < 0.001 |
MAC | 412 (9.03%) | 57 (3.15%) | |
SRCC | 78 (1.71%) | 38 (2.10%) | |
CEA n (%) | |||
Normal | 990 (21.71%) | 237 (13.11%) | < 0.001 |
Abnormal | 3571 (78.29%) | 1571 (86.89%) | |
Radiotherapy n (%) | |||
No | 4103 (89.96%) | 1380 (76.33%) | < 0.001 |
Yes | 458 (10.04%) | 428 (23.67%) | |
Chemotherapy n (%) | |||
No | 1272 (27.89%) | 409 (22.62%) | < 0.001 |
Yes | 3289 (72.11%) | 1399 (77.38%) | |
T stage n (%) | |||
T1 and T2 | 207 (4.54%) | 762 (42.15%) | < 0.001 |
T3 and T4 | 4354 (95.46%) | 1046 (57.85%) | |
N stage n (%) | |||
N0 | 796 (17.45%) | 889 (49.17%) | < 0.001 |
N1 | 1656 (36.31%) | 783 (43.31%) | |
N2 | 2109 (46.24%) | 136 (7.52%) | |
Bone metastasis n (%) | |||
No | 4421 (96.93%) | 1666 (92.15%) | < 0.001 |
Yes | 140 (3.07%) | 142 (7.85%) | |
Liver metastasis n (%) | |||
No | 1254 (27.49%) | 416 (23.01%) | < 0.001 |
Yes | 3307 (72.51%) | 1392 (76.99%) | |
Lung metastasis n (%) | |||
No | 3683 (80.75%) | 1167 (64.55%) | < 0.001 |
Yes | 878 (19.25%) | 641 (35.45%) | |
Brain metastasis n (%) | |||
No | 4531 (99.34%) | 1778 (98.34%) | < 0.001 |
Yes | 30 (0.66%) | 30 (1.66%) |